Lantern Pharma Inc.

NasdaqCM:LTRN Stok Raporu

Piyasa değeri: US$33.8m

Lantern Pharma Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Panna Sharma

İcra Kurulu Başkanı

US$684.4k

Toplam tazminat

CEO maaş yüzdesi76.8%
CEO görev süresi6.3yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi4.9yrs
Yönetim Kurulu ortalama görev süresi6.3yrs

Son yönetim güncellemeleri

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Recent updates

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Nov 05
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jun 12
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Nov 06
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jul 20
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Apr 04
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Dec 19
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Sep 02
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Jul 14

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

May 20
Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Feb 02
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Oct 13
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Aug 24

Lantern Pharma: Drug Recycling With AI

Jun 08

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

May 05
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma reports Q1 results

May 03

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Feb 19
Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Jan 04

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Lantern: Early Stage 'Smart Drug' Discovery Company

Nov 25

CEO Tazminat Analizi

Panna Sharma'un ücretlendirmesi Lantern Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$684kUS$525k

-US$16m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$475k

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$622kUS$432k

-US$12m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$2mUS$384k

-US$6m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$332kUS$267k

-US$2m

Dec 31 2018US$353kUS$105k

-US$2m

Tazminat ve Piyasa: Panna 'ın toplam tazminatı ($USD 684.39K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 646.00K ).

Tazminat ve Kazançlar: Panna 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Panna Sharma (53 yo)

6.3yrs

Görev süresi

US$684,385

Tazminat

Mr. Panna Sharma has been the Chief Executive Officer and President of Lantern Pharma Inc. since July 26, 2018 and has been its Director since August 29, 2018. As Chief Executive Officer, Mr. Sharma overse...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Panna Sharma
President6.3yrsUS$684.39kVeri yok
David Margrave
CFO & Secretary6.4yrsUS$442.68kVeri yok
Kishor Bhatia
Chief Scientific Officer & Scientific Consultant4.9yrsUS$283.24kVeri yok
Nicole Leber
Investor Relations Associateno dataVeri yokVeri yok
Peter Nara
Co-Founder & Advisorno dataUS$794.00Veri yok
Ernest Kitt
Head of Clinical Operations1.7yrsVeri yokVeri yok
Marc Chamberlain
Chief Medical Officer of Starlight Therapeuticsless than a yearVeri yokVeri yok

4.9yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: LTRN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Panna Sharma
President6.3yrsUS$684.39kVeri yok
Vijay Chandru
Independent Director5.1yrsUS$46.00kVeri yok
Maria Maccecchini
Independent Director2.4yrsUS$51.00kVeri yok
Donald Keyser
Independent Chairman6.8yrsUS$56.00k0.39%
$ 131.2k
David Silberstein
Independent Director6.4yrsUS$46.00kVeri yok

6.3yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LTRN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).